For years, finasteride has been marketed as a simple cosmetic fix for hair loss. But beneath its promise of restored confidence lies a troubling reality—emerging evidence shows the drug may carry severe psychiatric side effects, including depression, anxiety, and even suicide.
A new review published in The Journal of Clinical Psychiatry by Prof. Mayer Brezis of the Hebrew University reveals that both regulators and manufacturers overlooked mounting signals for over two decades.
What the Review Found
- Eight major studies (2017–2023) consistently showed that men taking finasteride were more likely to suffer from mood disorders and suicidal thoughts compared to non-users.
- Reports came from multiple countries, including the U.S., Sweden, Canada, and Israel.
- The risk isn’t limited to use—some patients reported lingering symptoms months or years after stopping, known as post-finasteride syndrome.
Despite this, the drug remained widely prescribed since its 1997 FDA approval for male pattern baldness.
A Systemic Failure
- FDA Response: Depression was added as a possible side effect only in 2011, suicidality in 2022—far too late, critics argue.
- Corporate Silence: Merck, the manufacturer, did not conduct safety studies to explore psychiatric risks.
- Pharmacovigilance Gap: Regulators underreport cases. By 2011, only 18 suicides were linked to finasteride in FDA data, though global estimates suggest thousands.
Prof. Brezis describes this as a failure of pharmacovigilance, worsened by the drug’s “cosmetic” status, which kept scrutiny low.
The Biological Link
Finasteride blocks testosterone’s conversion to DHT. But in the process, it disrupts neurosteroids like allopregnanolone, crucial for mood regulation. This imbalance may explain the psychiatric side effects.
Animal studies even suggest changes in brain structure and neuroinflammation with long-term use.
What Does It Mean for Doctors in India?
- Hair Loss Is Not Just Cosmetic
Indian men often seek finasteride as a quick solution. Doctors must weigh the risks against the benefits and ensure that patients understand the potential side effects. - Mental Health Must Be Screened
Any patient considering or already using finasteride should be evaluated for psychiatric history. Mood symptoms should never be dismissed as “unrelated.” - A Trend Toward Transparency
Globally, regulators are being pressured to update warnings. Indian dermatologists and general practitioners must stay ahead by prioritizing patient safety and informed consent.
Learnings for Doctors
- Avoid prescribing finasteride casually for cosmetic purposes without thorough counselling.
- Monitor patients closely for mood changes, anxiety, or insomnia.
- Document and report adverse effects—Indian data is still limited but critical for shaping safer policies.
- Explore safer, holistic approaches to hair loss when possible.
At The Doctorpreneur Academy, doctors are already:
- Educating Patients about risks hidden behind “cosmetic” prescriptions.
- Building awareness on integrating dermatology with mental health care.
- Advocating for transparency in treatment risks and informed decision-making.
By combining clinical knowledge with entrepreneurial foresight, Academy doctors are leading the way in patient-first care models—where safety, dignity, and trust come before cosmetic gains.
Final Thoughts
Finasteride’s story is a cautionary tale. A drug promoted for appearance may have cost lives because red flags were ignored for too long. For doctors, the message is clear: every prescription carries responsibility—and even cosmetic drugs can have life-altering risks.
At The Doctorpreneur Academy, we prepare doctors to balance innovation with ethics, ensuring patients receive treatments that are not just effective but also safe.
👉 For Doctors: Want to stay informed about hidden risks in commonly prescribed drugs and learn how to communicate them effectively to patients? Join The Doctorpreneur Academy and build a safer, future-ready practice.
👉 To register for our next masterclass, please click here: https://linktr.ee/docpreneur
